Anika Therapeutics vs OraSure Technologies
OraSure Technologies reported revenue of $115 million in fiscal 2025, about the same as Anika Therapeutics' $113 million in fiscal 2025. Anika Therapeutics' revenue fell 5.9% in its latest year, and OraSure Technologies' fell 38.1%. Anika Therapeutics had an operating margin of -9.8%, against -62.6% at OraSure Technologies. Free cash flow was $4 million at Anika Therapeutics and −$53 million at OraSure Technologies.
Side by side
| Anika Therapeutics | OraSure Technologies | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $113M | $115M |
| Revenue growth | −5.9% | −38.1% |
| Revenue growth a year, last 5 years | −2.9% | −7.7% |
| Gross margin | 56.6% | 41.9% |
| Operating margin | −9.8% | −62.6% |
| Net margin | −9.6% | −59.8% |
| Free cash flow | $4M | −$53M |
| Free cash flow margin | 3.9% | −46.3% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $10M | $15M |
| Change in diluted share count | −2.6% | −1.3% |
| Last close | $13.28 | $3.61 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $264,308, sold $0 | bought $456,495, sold $0 |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Anika TherapeuticsOraSure Technologies
Operating margin
Percent of revenue
Anika TherapeuticsOraSure Technologies
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Anika TherapeuticsOraSure Technologies
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Anika Therapeutics and OraSure Technologies pages.